Luca Del Medico

Tokura is building the operating system for ambulatory surgery in Germany. We design, build, and run ambulatory surgery centers, integrating space, people, processes, and technology into one system. Purpose-built for the demands of modern surgical care. To get patients back to their normal lives faster. Our ambition: 1 million surgeries per year.

Magdrive is developing the next generation of spacecraft propulsion for satellites today, deep space and beyond tomorrow. With high thrust and high efficiency at low mass, the Magdrive’s magnitude improvement in manoeuvrability enables entirely new missions and business models, including - high cadence avoidance manoeuvres in congested Low-Earth Orbit. - repeated rendezvous and close-proximity operations for satellite servicing and orbital manufacturing. - stochastic movement to make defense satellites untraceable.

Valink Therapeutics focusses on synergistic and non-obvious target combinations to create novel multivalent bispecific antibody-drug conjugates (bsADCs) that transform the treatment of solid tumors and other indications. Valink is a platform therapeutics company focussing on the discovery of bsADCs based out of Cambridge, MA and London, UK. The company is a VC-backed & Y Combinator (W21)-incubated spin-out of the University of Oxford, with over $20M total capital raised.

Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data.

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Tokura is building the operating system for ambulatory surgery in Germany. We design, build, and run ambulatory surgery centers, integrating space, people, processes, and technology into one system. Purpose-built for the demands of modern surgical care. To get patients back to their normal lives faster. Our ambition: 1 million surgeries per year.

Magdrive is developing the next generation of spacecraft propulsion for satellites today, deep space and beyond tomorrow. With high thrust and high efficiency at low mass, the Magdrive’s magnitude improvement in manoeuvrability enables entirely new missions and business models, including - high cadence avoidance manoeuvres in congested Low-Earth Orbit. - repeated rendezvous and close-proximity operations for satellite servicing and orbital manufacturing. - stochastic movement to make defense satellites untraceable.

Valink Therapeutics focusses on synergistic and non-obvious target combinations to create novel multivalent bispecific antibody-drug conjugates (bsADCs) that transform the treatment of solid tumors and other indications. Valink is a platform therapeutics company focussing on the discovery of bsADCs based out of Cambridge, MA and London, UK. The company is a VC-backed & Y Combinator (W21)-incubated spin-out of the University of Oxford, with over $20M total capital raised.

Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets. Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.

Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data.